Sorafenib treatment efficacy and KRAS biomarker status in the Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) trial. Background: A subset of lung ...

Investigators at Massachusetts General Hospital in Boston conducted an analysis of the fusion oncogene EML4-ALK and the more well-studied epidermal growth factor receptor (EGFR) mutation among a group ...

Researchers at Nano Life Science Institute (WPI-NanoLSI) and the Cancer Research Institute at Kanazawa University led have uncovered how targeted lung cancer drugs alter the shape and behavior of a ...

Break apart a couple worm-like chromosomes and they may reconnect with mismatched tips and tails – such is the case of the EML4-ALK fusion gene that creates 2-7 percent of lung cancers. Almost exactly ...

Heat shock protein 90 (Hsp90) is an abundant cellular chaperone protein that maintains the stability, activity and sorting of its protein substrates, which are also called client proteins (Young et al ...

In a scientific first, the fusion of two genes, ALK and EML4, has been identified as the genetic driver in an aggressive type of thyroid cancer, according to a study. These groundbreaking findings are ...

A new study identifies the RAS-MAPK pathway to be an Achilles' heel of EML4-ALK fusion-positive lung cancer and suggests that up-front combination therapy directed against both pathways can achieve ...

About five percent of lung adenocarcinomas, one of the most common forms of lung cancer, are driven by a faulty fusion of two genes, EML4 and ALK. This fusion results in different variants, and until ...

Genprex (GNPX) has entered into a Sponsored Research Agreement – SRA – with the University of Michigan Rogel Cancer Center to study TUSC2, the tumor suppressor gene used in Genprex’s lead drug ...

ExoDx Lung(ALK) is the World’s First Non-invasive Test Allowing Identification of Specific ALK Fusions Using Exosomal RNA-Based Liquid Biopsy ExoDx Lung(ALK) is the First in a Series of Exosomal ...